Learn how you can stall the development of full-blown Multiple Myeloma with evidence-based nutritional and supplementation therapies.
Click the orange button to the right to learn more.
A diagnosis of monoclonal gammopathy of undetermined significance is a double-edged sword. The good news is that you have caught a possible future incurable blood cancer early and may able to prevent your MGUS from becoming full-blown MM for years. The bad news is that you will now spend the rest of your life worrying about either your pre-MM or your MM.
Your other challenge with of diagnosis of any form of pre-cancer is that your oncologist will probably tell you that your only option is to watch and wait. I disagree. I am both a MM survivor and MM cancer coach. My experience and research have shown me that MGUS can be managed with evidence-based non-conventional therapies. I know of MGUS survivors who have been managing their pre-cancer for 15 years or more.
To learn more about the evidence-based protocols you can follow to prevent your Pre-Myeloma from becoming Multiple Myeloma, please watch the short video below:
Dr. Stephen Cohen–Have you ever wanted to read the notes and observations of a practicing compassionate and empathetic doctor who has cared for cancer patients for over 40 years? Well, now you can! Dr. Stephen Cohen, a medical oncologist and hematologist practicing in San Antonio, Texas, has kept a daily journal of interesting medical info and tidbits he encounters day to day from his personal experiences with patient care, professional journals he reads, and medically relevant information on all subjects that he comes across.
Multiple Myeloma evolves from a monoclonal gammopathy of undetermined significance (MGUS).
Only 10% of patients with newly diagnosed myeloma have a history of pre-existing MGUS.
MGUS almost always precedes myeloma.
Smoldering myeloma is an intermediate stage between MGUS and myeloma is associated with a higher risk of progression of approximately 10% year.
MGUS arises from a premalignant proliferation of monoclonal plasma cells derived from post-germinal B cells, that undergo genetic and microenvironmental changes leading to the transformation of these cells into a malignant process.
MGUS is a disorder of the terminally differentiated B lymphocytes, called plasma cells.
Plasma cells secrete monoclonal immunoglobulin, IgG in about 60%, IgA in about 20%, for light chains in 20%, IgD in 2%, and OgM in 0.5%, and in about 2-3% no detectable M protein.
Recent diagnostic criteria have included specific biomarkers such as clonal bone marrow plasma cells equal or greater than 60%, serum free light chain ratio equals greater than 100, and one focal lesion on MRI imaging which was added to markers of end-stage organ damage- hypercalcemia renal insufficiency, anemia, or bone lesions.
At least 50% of patients with clonal plasma cell proliferation in monoclonal gammopathy of unknown significance (MGUS) translocations involving the immunoglobulin heavy chain (IgH) locus on chromosome 14q32 evolve into myeloma.